Griseofulvin
(Fulvicin P/G, Fulvicin U/F, Gris-Peg, Grisactin)
Category:
Description:
Indications:
-
Fungal
infections of the skin, hair, and nails caused by susceptible
organisms.
-
Antifungal
spectrum usually includes: Trichophyton
rubrum, T. tonsurans, T. mentagropytes, T. interdigitalis, T.
verrucosum, T. megninii, T. gallinae, T. crateriform, T. sulphureum,
T. schoenleinii, Microsporum audouinii, M. canis, M. gypseum,
Epidermophyton floccosum
Contraindications:
-
Porphyria
-
Hepatocellular
failure
Precautions:
Adverse
Reactions (Side Effects):
-
CNS:
dizziness, fatigue, headache, insomnia, mental confusion, paresthesias
-
GI:
diarrhea, epigastric distress, BI bleeding, hepatic toxicity, nausea,
oral thrush, vomiting
-
GU:
menstrual irregularities, proteinuria
-
HEME:
granulocytopenia, leukopenia
-
SKIN:
angioneurotic edema, photosensitivity, rash, urticaria
|
Dosage:
Administered
orally (microsize tablets, ultramicrosize tablets, suspension)
-
Adult:
(microsize) PO 500-1000mg daily in single or divided doses; (ultramicrosize)
330-375mg daily in single or divided doses, max 750mg daily
-
Child:
> or = 2 years: PO (microsize) 10-15 mg/kg/day in single or divided
doses; (ultramicrosize) 5.5-7.3 mg/kg/day in single or divided dose
Duration of Treatment:
Condition |
Duration |
Tinea
corporis |
2-4
weeks |
Tinea
capitis |
at
least 4-6 weeks |
Tinea
pedis |
4-8
weeks |
Tinea
unguium |
3-6
months |
Drug
interactions:
-
Reduces
the response of : Aspirin, Cyclosporine, Oral Contraceptives,
Tacrolimus, and Warfarin
-
Phenobarbital:
reduces plasma griseofulvin level
Special
considerations:
-
Prior
to therapy, the type of fungus responsible for infection should be
identified
-
Response
to therapy may not be apparent for some time; complete entire course
of therapy
-
Avoid
prolonged exposure to sunlight
-
Clinician
should be notified if sore throat or skin rash occurs
-
Store
suspension at room temperature in light-resistant container
|
Home
· Military Medicine
· Sick Call · Basic Exams
· Medical Procedures
· Lab and X-ray · The Pharmacy
· The Library · Equipment
· Patient Transport
· Medical Force
Protection · Operational Safety · Operational
Settings · Special
Operations · Humanitarian
Missions · Instructions/Orders · Other Agencies · Video Gallery
· Forms · Web Links · Acknowledgements
· Help · Feedback Approved for public release;
Distribution is unlimited. The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.
Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by The Brookside Associates, LLC. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
© 2015, Brookside Associates, LLC. All rights reserved
Other Brookside Products
|
|